Microbot Medical appoints Francois H Cornelis to scientific advisory board


microbot libertyMicrobot Medical, the developer of the LIBERTY Robotic Surgical System, the first single-use endovascular robotic system, today announces the expansion of its global team of experts supporting the company as scientific advisory board (SAB) members, with Francois H Cornelis joining Microbot’s SAB.

Cornelis is an interventional radiologist who specialises in neuro interventions and image-guided minimally invasive therapies that allow for pain palliation and tumour control in the bones and spine. Professor Cornelis uses a variety of technologies to treat tumours and cancer-related pain, such as radiofrequency and microwave energy, cryotherapy, focused ultrasound, and electroporation, as well as image-guided modalities, including navigation software, magnetic resonance imaging (MRI), robotics, and positron emission tomography and computed tomography (PET-CT)-guided procedures. He is pursuing research, mainly into intra-arterial therapies for brain tumours and in the fields of mentoplasty, osteoplasty, and fixation, which help reinforce bones to reduce pain.

Cornelis received his MD in 2003 and completed his radiology training and his fellowship in 2008 and 2010, respectively, at the University of Bordeaux in France. He stayed on the faculty, with appointments in Radiology at the Bergonié Institute (2010) and the University of Bordeaux (2012). He was appointed as a tenured professor of radiology in France in 2017 and served as chief of the department of interventional radiology and oncology at the Sorbonne University in Paris before heading to New York.

“The support and endorsement of a global leader such as Cornelis is a vote of confidence and a great honour for the company. Cornelis joins a team of global leaders in their fields that are already serving as members of our SAB,” said Eyal Morag, chief medical officer of Microbot Medical. “The significant contributions of our SAB members to the company, including their participation in our pre-clinical studies, is expected to greatly support our forthcoming plans, including clinical trials and collaborations with leading medical centres worldwide.”


Please enter your comment!
Please enter your name here